Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
The Ewha Medical Journal ; : 50-54, 2017.
Article in English | WPRIM | ID: wpr-95356

ABSTRACT

Constipation is a prevalent, often chronic, gastrointestinal motility disorder. Bisacodyl, a stimulant laxative, is widely used to treat constipation in adults and children. This drug is usually safe, but it has some side effects including diarrhea, abdominal pain, colitis, and proctitis. There have been reports that rectal administration of bisacodyl could cause injury to the rectal mucosa by mechanical and chemical mechanisms. However, there has been no report of severe proctitis with rectal ulcers in patients taking oral bisacodyl. In this report, we describe the case of an 80-year-old woman with severe rectal ulcers and proctitis after taking oral bisacodyl for several days, and review the literature.


Subject(s)
Adult , Aged, 80 and over , Child , Female , Humans , Abdominal Pain , Administration, Rectal , Bisacodyl , Colitis , Constipation , Diarrhea , Gastrointestinal Motility , Mucous Membrane , Proctitis , Rectum , Ulcer
2.
Journal of Korean Diabetes ; : 178-184, 2014.
Article in Korean | WPRIM | ID: wpr-726964

ABSTRACT

Atypical antipsychotics, which have better efficacy and fewer side effects compared to first-generation antipsychotics, are being used increasingly for the treatment of schizophrenia. However, adverse events such as weight gain, diabetes mellitus and abnormal lipid profile have been reported in patients treated with these agents. Diabetic ketoacidosis (DKA) is a rare side effect of atypical antipsychotics, but deserves attention due to its severity. Although various atypical antipsychotics have been reported as causing DKA, there have been no reports showing an association with DKA and paliperidone, which is a recently developed antipsychotic agent. Here, we report two cases of DKA in patients with paliperidone therapy. Both cases had no history of diabetes before use of paliperidone, and DKA was manifested within 2 years of starting paliperidone therapy. Like other atypical antipsychotics, use of paliperidone warrants monitoring for metabolic derangements including DKA.


Subject(s)
Humans , Antipsychotic Agents , Diabetes Mellitus , Diabetic Ketoacidosis , Schizophrenia , Weight Gain
SELECTION OF CITATIONS
SEARCH DETAIL